Acquiring Company
Ipsen
Acquired Company
ImCheck Therapeutics
Boulogne-BillancourtFranceManufacturingBiotechnologyBiotechnologyHealth CareTherapeuticsDescription
Ipsen has successfully completed the acquisition of ImCheck Therapeutics, enhancing its oncology pipeline. This acquisition aligns with Ipsen's commitment to bringing transformative medicines to patients. ImCheck is known for its innovative immuno-oncology therapies.
Quick answer
Ipsen is acquiring ImCheck Therapeutics, announced December 15, 2025. Ipsen is based in Boulogne-Billancourt, Ile De France, France.
- How much did Ipsen pay for ImCheck Therapeutics?
- The deal value was not disclosed.
- What does Ipsen do?
- Ipsen: a global specialty-driven biopharmaceutical group focused on innovation and specialty care.
- Where are Ipsen and ImCheck Therapeutics based?
- Ipsen is based in Boulogne-Billancourt, Ile De France, France. ImCheck Therapeutics is based in France.
- Who are the decision-makers at Ipsen?
- Fundz holds 3 contacts at Ipsen. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Therapeutics and Manufacturing
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- AbbVie to acquire Revolution Medicines soon (January 9, 2026)
- Pfizer completes $43 billion acquisition of Seagen, $43B (January 4, 2026)
- BioNTech completes acquisition of CureVac (December 20, 2025)
- BioMarin to acquire Amicus for $4.8 billion, $4.8B (December 19, 2025)
- Day One to acquire Mersana for $130 million, $130M (November 30, 2025)
- ClearPoint Neuro acquires IRRAS for $5 million, $5M (November 20, 2025)
Who to call at Ipsen, and when
When Ipsen changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Ipsen raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Ipsen, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Ipsen. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Ipsen makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired ImCheck Therapeutics?
ImCheck Therapeutics was acquired by Ipsen, based in Boulogne-Billancourt. The deal was reported on December 15, 2025. Ipsen: a global specialty-driven biopharmaceutical group focused on innovation and specialty care. Our goal is to leave no patient behind. Ipsen is privately held and operates in Manufacturing.
When did Ipsen acquire ImCheck Therapeutics?
Ipsen's acquisition of ImCheck Therapeutics was reported on December 15, 2025. Ipsen has successfully completed the acquisition of ImCheck Therapeutics, enhancing its oncology pipeline. This acquisition aligns with Ipsen's commitment to bringing transformative medicines to patients. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does ImCheck Therapeutics do?
ImCheck Therapeutics is a private biotechnology company specializing in next-generation immuno-oncology therapies. The company is known for its pioneering work on innovative treatments targeting critical immune-regulatory pathways in cancer. It is privately held, operating in Biotechnology, and is based in France.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.